VP-16-resistant lung cancer cells have been shown to display elevated levels of histone deacetylase 4 (HDAC4) and concomitant treatment with both trichostatin A (an HDAC inhibitor) and VP-16 resulted in enhanced cell death in lung cancer cells [245]. This evidence concerns the gene HDAC4 and lung carcinoma.